126 related articles for article (PubMed ID: 7236870)
1. Bioavailability of sustained release propranolol formulations.
McAinsh J; Baber NS; Holmes BF; Young J; Ellis SH
Biopharm Drug Dispos; 1981; 2(1):39-48. PubMed ID: 7236870
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations.
Perucca E; Grimaldi R; Gatti G; Caravaggi M; Crema F; Lecchini S; Frigo GM
Br J Clin Pharmacol; 1984 Jul; 18(1):37-43. PubMed ID: 6743489
[TBL] [Abstract][Full Text] [Related]
3. The use of long-acting propranolol ('Inderal' LA) in the management of elderly hypertensive patients.
Hamdy C; Tovey D; Baber NS; McAinsh J
Eur J Clin Pharmacol; 1982; 22(5):379-81. PubMed ID: 7117349
[TBL] [Abstract][Full Text] [Related]
4. Theoretical Michaelis-Menten elimination model for propranolol.
McAinsh J; Gay MA
Eur J Drug Metab Pharmacokinet; 1985; 10(3):241-5. PubMed ID: 4085525
[TBL] [Abstract][Full Text] [Related]
5. Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions.
Byrne AJ; McNeil JJ; Harrison PM; Louis W; Tonkin AM; McLean AJ
Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):45S-50S. PubMed ID: 6743474
[TBL] [Abstract][Full Text] [Related]
6. Long-acting propranolol in the prophylaxis of migraine: a comparative study of two doses.
Carroll JD; Reidy M; Savundra PA; Cleave N; McAinsh J
Cephalalgia; 1990 Apr; 10(2):101-5. PubMed ID: 2193712
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability and in-vitro/in-vivo correlation for propranolol hydrochloride extended-release bead products prepared using aqueous polymeric dispersions.
Rekhi GS; Jambhekar SS
J Pharm Pharmacol; 1996 Dec; 48(12):1276-84. PubMed ID: 9004191
[TBL] [Abstract][Full Text] [Related]
8. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability of propranolol and bendrofluazide formulations.
McAinsh J; Holmes BF; Baber NS; Young J
Biopharm Drug Dispos; 1981; 2(2):167-75. PubMed ID: 7248480
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability of propranolol hydrochloride tablet formulations: application of multiple dose crossover studies.
Eldon MA; Kinkel AW; Daniel JE; Latts JR
Biopharm Drug Dispos; 1989; 10(1):69-76. PubMed ID: 2923962
[TBL] [Abstract][Full Text] [Related]
11. Propranolol in cardiac arrhythmias: a comparative study of the conventional and long-acting formulations.
Kubik MM; Gill B; Dawes PM
Curr Med Res Opin; 1986; 10(4):215-20. PubMed ID: 3780285
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
[TBL] [Abstract][Full Text] [Related]
13. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
14. Identification of formulation and manufacturing variables that influence in vitro dissolution and in vivo bioavailability of propranolol hydrochloride tablets.
Eddington ND; Ashraf M; Augsburger LL; Leslie JL; Fossler MJ; Lesko LJ; Shah VP; Rekhi GS
Pharm Dev Technol; 1998 Nov; 3(4):535-47. PubMed ID: 9834957
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic evaluation of conventional and controlled release dosage form of propranolol.
Das SK; Chattaraj SC
Arzneimittelforschung; 1990 Jul; 40(7):752-4. PubMed ID: 2222550
[TBL] [Abstract][Full Text] [Related]
16. The relative bioavailability of a commercial propranolol hydrochloride tablet in man.
Roscoe R; Cooper J; Wilson TW; Joshi NN; Midha KK
Biopharm Drug Dispos; 1982; 3(2):105-14. PubMed ID: 7104460
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics and pharmacological actions of a long-acting formulation of propranolol.
Ohashi K; Ebihara A; Kondo K; Usami M
Arzneimittelforschung; 1984; 34(4):507-12. PubMed ID: 6378211
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
[TBL] [Abstract][Full Text] [Related]
19. Comparison of a once daily long-acting formulation of propranolol with conventional propranolol given twice daily in patients with mild to moderate hypertension.
Douglas-Jones AP
J Int Med Res; 1979; 7(3):221-3. PubMed ID: 378731
[TBL] [Abstract][Full Text] [Related]
20. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
